Physician profile
Grayson E Mcconnell
NPI 1871026070
$1,650.95
in general payments reported to CMS, 2019-2025
27 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.53 · 2022: $253 · 2023: $390 · 2024: $503 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,384.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,383.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $201.58 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $162.94 | 2023-2025 | |
| Amgen INC. | $155.62 | 2021-2025 | Evenity, Prolia, Repatha |
| Abbvie INC. | $147.14 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $144.64 | 2022-2025 | Airsupra, Farxiga, Andexxa |
| Lilly USA, LLC | $67.13 | 2022-2024 | Jardiance, Lyumjev, Baqsimi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $66.10 | 2024-2025 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $65.98 | 2023-2025 | Gvoke Hypopen |
| Astellas Pharma US INC | $63.57 | 2023-2024 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.90 | 2023-2024 | Jardiance |
| Inspire Medical Systems, INC. | $52.51 | 2025 | Inspire |
| Merck Sharp & Dohme LLC | $49.50 | 2022-2023 | Verquvo, Belsomra |
| Bayer Healthcare Pharmaceuticals INC. | $48.17 | 2024-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $41.05 | 2022 | |
| Glaxosmithkline, LLC. | $39.88 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $38.13 | 2025 | General - Erectile Dysfunction |
| E.R. Squibb & Sons, L.L.C. | $34.94 | 2024 | Eliquis |
| Exact Sciences Corporation | $32.08 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Orthofix Medical, INC. | $25.49 | 2024 | Physio-Stim |
| Janssen Pharmaceuticals, INC | $23.28 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.74 | 2024 | Caplyta |
| Corcept Therapeutics | $21.58 | 2025 | Korlym |
| Stryker Corporation | $19.23 | 2025 | Clottriever Bold Catheter |
| Dexcom, INC. | $19.01 | 2024 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $18.99 | 2022 | |
| Axsome Therapeutics, INC. | $18.98 | 2025 | Auvelity |
| Alexion Pharmaceuticals, INC. | $12.79 | 2023 | Strensiq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Grayson Mcconnell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.